Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, will be a featured presenter in both the CEO Roadshow Webinar series and the Benzinga Healthcare Small Cap Conference.Genprex president and CEO Rodney Varner will be presenting at both events, with the presentations focused on the company’s novel gene therapy pipeline in cancer and diabetes. The CEO Roadshow will be held on Sept. 22, 2021, with Varner’s presentation scheduled to start at 11 a.m. ET. The CEO Roadshow webinar series is designed to shine a spotlight on both small and mid-cap stocks that have near-term strategies or actions that making them potential long-term investment opportunities. The two-day Benzinga Healthcare Small Cap Conference is slated for Sept. 28–29, 2021, with the Genprex presentation scheduled for Sept. 29 at 1:15 p.m. ET. The Benzinga Small Cap Conferences provide an intimate, virtual opportunity for small cap companies, investors and traders alike to connect and learn about potential small cap investment options. In both instances, Varner will also be available for questions following each presentation.
To view the presentations, visit
https://ibn.fm/kFGL9 and
https://ibn.fm/6UJB7
To view the full press release, visit
https://ibn.fm/Nscwr
About Genprex Inc.
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, nonviral ONCOPREX(R) Nanoparticle Delivery System, which the company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles, with the resultant product then being administered intravenously, where it is taken up by tumor cells that express proteins that are deficient. Genprex’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR (“EFGR”) mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at
www.Genprex.com
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at
http://ibn.fm/GNPX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.